These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33108124)

  • 21. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.
    Duits LC; Klaver E; Bureo Gonzalez A; Boerwinkel DF; Ten Kate FJW; Offerhaus GJA; Meijer SL; Visser M; Seldenrijk CA; Krishnadath KK; Schoon EJ; Weusten BLAM; Mallant-Hent RC; Pouw RE; Bergman JJGHM
    Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 29873685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus.
    Almond LM; Hutchings J; Lloyd G; Barr H; Shepherd N; Day J; Stevens O; Sanders S; Wadley M; Stone N; Kendall C
    Gastrointest Endosc; 2014 Jan; 79(1):37-45. PubMed ID: 23886354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of a Classification System to Identify High-Grade Dysplasia and Esophageal Adenocarcinoma in Barrett's Esophagus Using Narrow-Band Imaging.
    Sharma P; Bergman JJ; Goda K; Kato M; Messmann H; Alsop BR; Gupta N; Vennalaganti P; Hall M; Konda V; Koons A; Penner O; Goldblum JR; Waxman I
    Gastroenterology; 2016 Mar; 150(3):591-8. PubMed ID: 26627609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.
    Gatenby P; Bhattacharjee S; Wall C; Caygill C; Watson A
    World J Gastroenterol; 2016 Dec; 22(48):10592-10600. PubMed ID: 28082811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score).
    Brown CS; Lapin B; Goldstein JL; Linn JG; Talamonti MS; Carbray J; Ujiki MB
    Ann Surg; 2018 Apr; 267(4):716-720. PubMed ID: 28230661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
    Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
    Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
    Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
    Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
    Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
    Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
    Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
    Davison JM; Goldblum JR; Duits LC; Khoshiwal AM; Bergman JJ; Falk GW; Diehl DL; Khara HS; Smolko C; Arora M; Siegel JJ; Critchley-Thorne RJ; Thota PN
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00631. PubMed ID: 37622544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
    Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
    J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
    Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.